 Forma Therapeutics Holdings Inc NASDAQ: FMTX has presented blinded data on sickle cell disease patients who received 600 mg of FT-4202, a pyruvate kinase R activator. The 600 mg high-dose cohort featured fewer hemoglobin responders than the 300-mg arm, but FT-4202 showed a similar safety and tolerability profile as the 300 mg cohort, despite the doubling of the dose. 